Elizabeth Diaz, NP

Panelists discuss how the October 2024 FDA approval of inavolisib in combination with palbociclib and fulvestrant for HR positive (HR+)/ HER2 negative  (HER2-) metastatic breast cancer with a PIK3CA mutation marks a pivotal advancement in precision medicine, highlighting how agents like such as inavolisib, capivasertib, elacestrant, and alpelisib have transformed treatment approaches and expanded therapeutic options for patients.

Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.